NY-CARESTREAM-HEALTH
20.2.2024 21:42:30 CET | Business Wire | Press release
Carestream Health will exhibit its expanding portfolio of innovative, industry-leading medical imaging solutions at the annual European Congress of Radiology (ECR) from 28th February to 3rd March in Vienna Building on its century-long foundation of imaging research science, the company will showcase its diagnostic imaging solutions that help improve clinical outcomes, enhance the imaging experience for users and patients, and strengthen the financial position of healthcare facilities.
“We understand that the radiology industry across the world is facing challenges such as a shortage of skilled staff and consequently radiologists are dealing with increased workload demands,” said Jane Moverley, International Sales Director, Digital Radiology. “This is why Carestream solutions add significant value to the imaging process. For example, our new DRX-LC Detector helps deliver high-quality, long-length imaging with a single exposure to deliver a more user-friendly workflow, optimize productivity, and ease the physical stress on radiographers. We are also showcasing our expanding line of X-ray solutions that deliver high-quality imaging to meet our customers’ needs at an affordable price.”
Solutions to Help Improve Clinical Outcomes
DRX-Compass X-ray System
- Exceptional image quality
- Scalable and upgradeable technology
- Available in floor-mount or OTC configuration
DRX-Revolution Mobile X-ray System
- Our original X-ray Room on Wheels offering provides superb image quality, maneuverability, and on-board storage.
- Robust functionality with Carestream’s most advanced image processing is available in a single platform.
- Low-profile design and flexibility mean you can easily capture images wherever you need them most.
Solutions to Enhance User and Patient Experience
DRX-LC Detector
- Captures long-length images with a single exposure
- Saves exam time and speeds up workflow
- Decreases retakes
- Allows a higher level of patient comfort
ImageView Software
- Provides high-image quality with AI and advanced image processing technology
- Delivers a quick and sleek operator experience via a single-screen workflow
- Allows users to track analytics on key parameters such as exposure rates and number of rejections
- Provides dose reporting
Solutions to Strengthen Financial Position
New DRX-Rise Mobile X-ray System
- Cutting-edge features in a fully-integrated, digital X-ray unit provide an affordable path to digital imaging.
- Efficiency-boosting features include two touchscreen displays, a state-of-the-art lithium battery, and in-bin detector charging.
- Bedside imaging minimizes disruption and helps deliver an improved patient experience.
DR Detectors
- These are the right detector for every facility, workflow, and budget.
- X-Factor capability lets you share detectors across your facility.
- Upgrade your existing film or CR systems to full wireless DR with a retrofit system and detector.
- Various cassette sizes let you choose the best fit.
Full Suite of Imaging Solutions on Display at ECR 2024
Carestream will also display additional imaging innovations at Expo X2-Booth 220 at ECR. These will include the DRX-Compass X-ray System, DRX-Rise Mobile X-ray System, and DRX-Revolution Mobile X-ray System, as well as our suite of DR Detectors.
Schedule an appointment to discuss Carestream’s latest innovations and other medical imaging solutions at ECR 2024.
About Carestream Health
Carestream is a worldwide provider of medical imaging systems; X-ray imaging systems for non-destructive testing; and precision contract coating services for a wide range of industrial, medical, electronic, and other applications—all backed by a global service and support network. For more information about the company’s broad portfolio of products, solutions, and services, please contact your Carestream representative, or call 1-888-777-2072, or visit www.carestream.com.
CARESTREAM is a trademark of Carestream Health.
“Rx only”
2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220770604/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom